



RUBYnanomed

RUBYnanomed offers a non-invasive tool for early diagnosis and monitoring of cancer metastasis


Area	Diagnostics
Headquarter	Braga, Portugal
Countries of operation	Global
Founding year	2018
Status	Prototype

RUBYnanomed is a spin-off from the International Nanotechnology laboratory (INL), that wants to bring to market the RUBYchip™: a device (microfluidic-based cartridge) that isolates, enumerates and phenotypes circulating tumour cells (CTCs) directly from whole blood samples.

RUBYnanomed vision is to develop a POC Instrument to give oncologists a tool for real time monitoring of the metastasis evolution during treatment, enabling the prediction of disease evolution and drug resistance.

RUBYchip™ can also be used as a Companion Diagnostics finding new therapeutic targets for personalized medicine.

Incubator programme	N/A
Approvals	N/A
Awards	N/A
Patents	PCT/EP2016/078406
Revenue (last yr)	N/A
Funds raised	€3M grant funding
Currently raising:	€800k



Interested? Get in touch

✉ greg@clab.ventures
www.rubynanomed.com

